Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim Group

Galmed Pharmaceuticals (NASDAQ:GLMD) received a $14.00 price target from research analysts at Maxim Group in a report released on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 74.56% from the company’s previous close.

GLMD has been the subject of several other reports. Roth Capital initiated coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 target price for the company. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Seaport Global Securities restated a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 27th. Finally, Zacks Investment Research lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.30.

Galmed Pharmaceuticals (GLMD) traded up $0.07 during mid-day trading on Wednesday, reaching $8.02. 17,700 shares of the company traded hands, compared to its average volume of 35,077. Galmed Pharmaceuticals has a fifty-two week low of $3.04 and a fifty-two week high of $9.59.

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned 0.15% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim Group” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/06/galmed-pharmaceuticals-glmd-given-a-14-00-price-target-at-maxim-group.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

What are top analysts saying about Galmed Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galmed Pharmaceuticals Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit